COX-2 expression in pseudomyxoma peritonei

Cancer Letters

Volumn 244, Issue 1, 2006, Pages 86-90

  Gatalica, Zoran ^a   Loggie, Brian ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Appendix; Colon cancer; COX 2; EGFR; Her 2; Pseudomyxoma peritonei; Targeted therapy

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; APPENDICEAL NEOPLASMS; CYCLOOXYGENASE 2; CYSTADENOMA, MUCINOUS; ENDOTHELIAL CELLS; EPITHELIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; PSEUDOMYXOMA PERITONEI; RECEPTOR, ERBB-2; STROMAL CELLS;

EID: 33749261636     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.12.013     Document Type: Article

References (28)

1. Ronnett B.M., Zahn C.M., Kurman R.J., Kass M.E., Sugarbaker P.H., and Shmookler B.M. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to 'pseudomyxoma peritonei'. Am J. Surg. Pathol. 19 (1995) 1390-1408
2. Ronnett B.M., Yan H., Kurman R.J., Shmookler B.M., Wu L., and Sugarbaker P.H. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis then patients with peritoneal mucinous carcinomatosis. Cancer 92 (2001) 85-91
3. Ronnett B.M., and Seidman J.D. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. Am J. Surg. Pathol. 27 5 (2003) 650-657
4. van Ruth S., Acherman Y.I., van de Vijver M.J., Hart A.A., Verwaal V.J., and Zoetmulder F.A. Pseudomyxoma peritonei: a review of 62 cases. Eur J. Surg. Oncol. 29 8 (2003) 682-688
5. Sinicrope F.A., and Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 23 1-2 (2004) 63-75
6. T.K. Asano, R.S. McLeod, Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas (cochrane review), in: Cochrane Library, Issue 3, Wiley, Chichester, UK, 2004.
7. Ronnett B.M., Shmookler B.M., Diener-West M., Sugarbaker P.H., and Kurman R.J. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int. J. Gynecol. Pathol. 16 (1997) 1-9
8. O'Connel J.T., Tomlinson J.S., Roberts A.A., McGonigle K.F., and Barsky S.H. Pseudomyxoma peritonei is a disease of MUC2 expressing goblet cells. Am. J. Pathol. 161 (2002) 551-564
9. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24 (2003) 96-102
10. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 4 (1994) 1183-1188
11. Yu W., Murray N.R., Weems C., Chen L., Guo H., Ethridge R., et al. Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis. J. Biol. Chem. 278 13 (2003) 11167-11174
12. Shao J., Evers B.M., and Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J. Biol. Chem. 279 (2004) 14287-14293
13. Pai R., Soreghan B., Szabo I.L., pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8 (2002) 289-293
14. Daniels W., Hatcher L., Loggie B., and Gatalica Z. Her-2 neu in pseudomyxoma peritonei. Arch. Pathol. Lab. Med. 129 (2005) 558 (abstract)
15. Mann M., Sheng H., Shao J., Williams C.S., Pisacane P.I., Sliwkowski M.X., and DuBois R.N. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120 7 (2001) 1713-1719
16. Wiese F.W., Thompson P.A., Warneke J., Einspahr J., Alberts D.S., and Kadlubar F.F. Variation in cyclooxygenase expression levels within the colorectum. Mol. Carcinog. 37 1 (2003) 25-31
17. Sinicrope F.A., Lemoine M., Xi L., Lynch P.M., Cleary K.R., Shen Y., and Frazier M.L. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology 117 2 (1999) 350-358
18. Karnes Jr. W.E., Shattuck-Brandt R., Burgart L.J., DuBois R.N., Tester D.J., Cunningham J.M., et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res. 58 23 (1998) 5473-5477
19. Umar A., Boland C.R., Terdiman J.P., Syngal S., de la Chapelle A., Ruschoff J., et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96 4 (2004) 261-268
20. Kabbani W., Houlihan P.S., Luthra R., Hamilton S.R., and Rashid A. Mucinous and nonmucinous appendiceal adenocarcinomas: different clinicopathological features but similar genetic alterations. Mod. Pathol. 15 6 (2002) 599-605
21. Gatalica Z., Knezetic J., Choquette J., Linder-Stephenson L., Loggie B., and Lynch H.T. Microsatellite instability in patients with peritoneal mucinous carcinomatosis. J. Mol. Diagn. 6 (2004) 152 abstract
22. Adegboyega P.A., Ololade O., Saada J., Mifflin R., Di Mari J.F., and Powell D.W. Subepithelial myofibroblasts express cyclo-oxygenase-2 in colorectal tubular adenomas. Clin. Cancer Res. 10 17 (2004) 5870-5879
23. Cruz-Correa M., Hylind L.M., Romans K.E., Booker S.V., and Giardiello F.M. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 122 3 (2002) 641-645
24. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., et al. FAP study group. a randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 6 (2002) 857-860
25. Shih I.M., Yan H., Speyrer D., Shmookler B.M., Sugarbaker P.H., and Ronnett B.M. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. Am. J. Surg. Pathol. 25 8 (2001) 1095-1099
26. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.L., West A.B., and Myofibroblasts I.I. Intestinal subepithelial myofibroblasts. Am. J. Physiol. 277 (1999) C183-C201
27. Frungieri M.B., Weidinger S., Meineke V., Köhn F.M., and Mayerhofer A. Proliferative action of mast-cell tryptase is mediated be PAR2, COX-2, prostaglandins, and PPARγ: possible relevance to human fibrotic disorders. Proc. Natl Acad. Sci. USA 99 (2002) 15072-15077
28. Miyajima A., Ito K., Asano T., Seta K., Ueda A., and Hayakawa M. Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction?. J. Urol. 166 (2001) 1124-1129